BiotechTube

Imipenem + Imipenem

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ventilator Associated Pneumonia

Conditions

Ventilator Associated Pneumonia

Trial Timeline

Nov 1, 2011 → Jul 1, 2014

NCT ID
NCT01379157

About Imipenem + Imipenem

Imipenem + Imipenem is a approved stage product being developed by Merck for Ventilator Associated Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT01379157. Target conditions include Ventilator Associated Pneumonia.

What happened to similar drugs?

1 of 3 similar drugs in Ventilator Associated Pneumonia were approved

Approved (1) Terminated (2) Active (0)
✅Vancomycin + LinezolidPfizerApproved
❌Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
❌Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01379157ApprovedCompleted
NCT02213783ApprovedCompleted

Competing Products

9 competing products in Ventilator Associated Pneumonia

See all competitors
ProductCompanyStageHype Score
Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
32
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + DoripenemJohnson & JohnsonPhase 2
35
Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3
32
Vancomycin + LinezolidPfizerApproved
43
anidulafunginPfizerPhase 2
27
LinezolidPfizerPre-clinical
18
aerosolized vancomycin or gentamicinNektar TherapeuticsPhase 2
29
IC43 + PlaceboValneva SEPhase 2
29
CeftobiproleBasilea PharmaceuticaPhase 1
15